BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

Clinical Study to Evaluate the Efficacy and Safety of Three Different Doses of BAY1817080 Compared to Placebo in Patients With Chronic Cough

Phase 2

Completed

Conditions: Refractory and/or Unexplained Chronic Cough

Interventions: Drug: Placebo
Drug: BAY1817080

First Posted Date: 2020-09-24

Last Posted Date: 2022-08-18

Lead Sponsor: Bayer

Target Recruit Count: 310

Registration Number: NCT04562155

Locations: 🇧🇪
VZW Emmaus, Mechelen, Belgium
🇭🇺
Da Vinci Maganklinika, Pecs, Hungary
🇭🇺
Farmakontroll Bt., Szazhalombatta, Hungary

and more 96 locations

Study to Learn More About the Effect of a New Drug Called BAY2327949 on the Blood Flow Through Kidneys in Adult Participants With Moderate Chronic Kidney Disease

Phase 1

Terminated

Conditions: Moderate Chronic Kidney Disease

Interventions: Drug: BAY2327949
Drug: Placebo

First Posted Date: 2020-09-17

Last Posted Date: 2022-08-23

Lead Sponsor: Bayer

Target Recruit Count: 7

Registration Number: NCT04552262

Locations: 🇩🇰
Steno Diabetes Center Copenhagen, Herlev, Denmark

Clinical Study to Evaluate the Treatment Effect and Safety of BAY1817080 in Patients With Overactive Bladder (OAB)

Phase 2

Completed

Conditions: Overactive Bladder

Interventions: Drug: Placebo
Drug: BAY1817080

First Posted Date: 2020-09-11

Last Posted Date: 2022-12-22

Lead Sponsor: Bayer

Target Recruit Count: 99

Registration Number: NCT04545580

Locations: 🇦🇹
Medizinische Universität Graz, Graz, Steiermark, Austria
🇵🇹
Centro Hospitalar Universitario do Porto, Porto, Portugal
🇦🇺
Emeritus Research, Camberwell, Victoria, Australia

and more 24 locations

Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug

Phase 2

Completed

Conditions: End Stage Renal Disease Requiring Hemodialysis

Interventions: Drug: Fesomersen sodium (BAY2976217)
Drug: Placebo

First Posted Date: 2020-09-01

Last Posted Date: 2023-07-03

Lead Sponsor: Bayer

Target Recruit Count: 307

Registration Number: NCT04534114

Locations: 🇨🇦
Unity Health Toronto: St. Michael's Hospital, Toronto, Ontario, Canada
🇺🇸
Desert Cities Dialysis-Amethyst & Desert Cities Dialysis, Victorville, California, United States
🇺🇸
Fresenius Kidney Care Clovis, Clovis, California, United States

and more 66 locations

Study to Gather Information on the Acceptability of a New Flavor System With Increasing Levels of 2, 4, 6 g or Higher of Mannitol for PEG 3350 in Subjects Having Infrequent Bowel Movements.

Phase 4

Completed

Conditions: Constipation

Interventions: Drug: Polyethylene glycol (MiraLAX, BAY81-8430)
Drug: Mannitol

First Posted Date: 2020-09-01

Last Posted Date: 2020-11-12

Lead Sponsor: Bayer

Target Recruit Count: 50

Registration Number: NCT04534465

Locations: 🇺🇸
Merck Consumer Center, Memphis, Tennessee, United States

Study to Gather Information About the Actual Use of an Adhesive Patch Placed on the Skin to Deliver Oxytrol Through the Skin Into the Bloodstream.

Phase 3

Completed

Conditions: Overactive Bladder

Interventions: Drug: Oxybutynin (Oxytrol, BAY839380)

First Posted Date: 2020-09-01

Last Posted Date: 2020-10-20

Lead Sponsor: Bayer

Target Recruit Count: 855

Registration Number: NCT04534491

Locations: 🇺🇸
Stevenson Family Pharmacy, Saint Joseph, Missouri, United States

Study to Find Out Whether Participants With a History of Stuffy Nose Due to Allergic Reactions in the Nose Would Intend to Buy Drug Phenylephrine Hydrochloride Extended Release Tablets After Receiving it Once in This Study

Phase 3

Completed

Conditions: Nasal Congestion Due to Allergic Rhinitis

Interventions: Drug: Phenylephrine HCl (Sinus Comfort, BAY112476)

First Posted Date: 2020-09-01

Last Posted Date: 2020-09-01

Lead Sponsor: Bayer

Target Recruit Count: 347

Registration Number: NCT04534452

Locations: 🇺🇸
Allergy & Asthma Specialists, PC, Blue Bell, Pennsylvania, United States

Study to Find Out if Cream V61-044 Used to Treat Fungal Infections Causes an Allergic Skin Reaction to Sunlight in Healthy Participants

Phase 3

Completed

Conditions: Dermatitis, Photoallergic

Interventions: Drug: Butenafine HCl 1% (BAY1896425) - Induction Phase
Drug: Butenafine HCl 1% (BAY1896425) - Challenge Phase

First Posted Date: 2020-08-31

Last Posted Date: 2020-11-16

Lead Sponsor: Bayer

Target Recruit Count: 137

Registration Number: NCT04532164

Study to Determine Skin Irritation Potential of an Antifungal Cream Containing Trolamine After Repeated Skin Application (Cumulative Irritation Patch Test)

Phase 3

Completed

Conditions: Hypersensitivity

Interventions: Drug: Butenafine HCl 1% (BAY1896425)
Drug: Positive Control-Sodium lauryl sulfate (SLS)
Other: Negative Control

First Posted Date: 2020-08-31

Last Posted Date: 2020-09-25

Lead Sponsor: Bayer

Target Recruit Count: 32

Registration Number: NCT04531813

Study to Determine Skin Irritation and/or Sensitization Potential of an Antifungal Cream Containing Trolamine (Repeated Insult Patch Test)

Phase 3

Completed

Conditions: Hypersensitivity

Interventions: Drug: Butenafine HCl 1% (BAY1896425)

First Posted Date: 2020-08-28

Last Posted Date: 2020-11-17

Lead Sponsor: Bayer

Target Recruit Count: 225

Registration Number: NCT04531540

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy